QuantHealth Secures $45 Million in Latest Series B Funding Round

QuantHealth secured $45 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

QuantHealth Raises $45 million in Funding

QuantHealth uses AI to run patient-level simulations of clinical trials, letting pharma and biotech companies test thousands of trial-design variations before dosing a real patient.

Investors Behind the Funding

The round was backed by Qumra Capital. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

QuantHealth operates in Healthcare & Life Sciences. Clinical trial design is moving from expert judgment to simulation. Over 90% of drugs entering clinical development fail to reach market, and each failure carries nine-figure cost, so simulating trial outcomes in silico is one of the highest-leverage applications of AI in pharma. Sanofi Ventures and Bertelsmann Healthcare participating signals strategic pharma pull, not just financial interest.

Strategic Use of Funds

Accelerate adoption of its simulation-first clinical trial development platform

Looking Ahead

QuantHealth continues to attract investor attention following its latest financing.

Source reference: original announcement/article.